<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588818</url>
  </required_header>
  <id_info>
    <org_study_id>2020-ADA-Uveitis</org_study_id>
    <nct_id>NCT04588818</nct_id>
  </id_info>
  <brief_title>Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis</brief_title>
  <official_title>Adalimumab in Combination With Methotrexate for the Treatment of Non-infectious Panuveitis in Chinese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the efficacy and safety of ADA plus MTX for the&#xD;
      treatment in non-infectious pediatric panuveitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although non-infectious uveitis is rare in pediatric population, the irreversible visual&#xD;
      impairment due to ocular complications, severe drug adverse effects are disturbing. There is&#xD;
      a high rate of chronic disorder of ocular inflammation and unresponsiveness of therapy drugs&#xD;
      in pediatric uveitis, which result in structure destruction and functional impairment&#xD;
      including band keratopathy, posterior synechiae, cataract, and so on. The systemic and&#xD;
      topical glucocorticoid are advocated to control inflammation but carry a high risk of lots of&#xD;
      advert events.&#xD;
&#xD;
      Methotrexate is now highly recommended to control uveitis and most commonly prescribed in&#xD;
      pediatric uveitis. it was benefit to prolong remission and reduce recurrence. However,&#xD;
      despite early intervention 27-48% children do not achieve control of inflammation and 20%&#xD;
      experience adverse events. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal&#xD;
      antibody, is effective in the treatment of many rheumatic diseases. ADA as the initial&#xD;
      treatment in adult patients of uveitis lead to a more optimistic prognosis, a better visual&#xD;
      acuity and a lower dose of dosage of daily glucocorticoid.&#xD;
&#xD;
      The investigators propose to test the efficacy and safety of ADA plus MTX for the treatment&#xD;
      in non-infectious pediatric panuveitis who were followed up for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the time to reach the remission</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the time of a first relapse once remission</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular structure</measure>
    <time_frame>12 months</time_frame>
    <description>decrease of central foveal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the total dosage of corticosteriod or the time to steroid discontinuation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual Acuityand</measure>
    <time_frame>12 months</time_frame>
    <description>increase of BCVA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab plus Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab plus Methotrexate</intervention_name>
    <description>Adalimumab 40 mg (≥30kg weight) or 20mg (&lt;30kg weight) subcutaneously every other week without loading dose.&#xD;
Methotrexate(10 to 20 mg per square meter of body-surface area; maximum dose, 20 mg) .</description>
    <arm_group_label>Adalimumab plus Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of non-infectious panuveitis&#xD;
&#xD;
          -  Age from 2 to 16 years old&#xD;
&#xD;
          -  Vision threatening non-infectious uveitis hadn't received standardized systematic&#xD;
             treatment before&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had active infection (including hepatitis B or C infection,&#xD;
             tuberculosis), malignancy diseases, or bilateral irreversible blindness and any other&#xD;
             contraindications of ADA&#xD;
&#xD;
          -  previous exposure to another biologic agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Liang, MD</last_name>
    <phone>0086-20-87330402</phone>
    <email>liangd2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang, MD</last_name>
      <phone>0086-20-87330402</phone>
      <email>liangd2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Dan Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 17, 2020</last_update_submitted>
  <last_update_submitted_qc>October 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dan Liang</investigator_full_name>
    <investigator_title>M.D</investigator_title>
  </responsible_party>
  <keyword>Pediatric Panuveitis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

